GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aclaris Therapeutics
Aclaris Therapeutics is a biotech company focused on immunology and dermatology. Its stock price is highly volatile and driven by news of clinical trials. The stock chart is a history of binary events, where the success or failure of a trial can dramatically change the value.
Share prices of companies in the market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company focused on developing drugs to treat immune-inflammatory diseases. We've categorized it as "Pharma: Immunology." The chart below shows how investors value companies operating in this broad and competitive field of medicine.
Broad Market Index - GURU.Markets
Aclaris Therapeutics is a biopharmaceutical company focused on developing drugs to treat immune-inflammatory diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ACRS - Daily change in the company's share price Aclaris Therapeutics
Shares of Aclaris, a biopharmaceutical company, are highly volatile. change_co tracks investor reactions to news about clinical trials of its drugs. This metric is the basis for advanced biotech risk analysis formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Aclaris Therapeutics, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with ACRS, which focuses on immunology, helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Aclaris Therapeutics is a biotech company focused on immunology and dermatology. Its shares move in sync with clinical trial news. This high, event-driven volatility feeds into the overall market flow, making the picture more complex and multifaceted.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aclaris Therapeutics
For Aclaris Therapeutics, year-over-year performance is a story of its transition to developing drugs for the treatment of immunoinflammatory diseases. Its market capitalization over the next 12 months depends on progress in clinical trials of its kinase inhibitors. Success in this area could fundamentally transform the company after the sale of its previous assets.
Annual dynamics of market capitalization of the market segment - Pharma immune
Aclaris Therapeutics, Inc. is a clinical-stage biotech developing drugs for the treatment of inflammatory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aclaris Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aclaris Therapeutics
The market capitalization of Aclaris, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its drugs for the treatment of inflammatory diseases, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Aclaris Therapeutics is a biotech company specializing in immunology and dermatology. Its sector is extremely sensitive to clinical trial results and regulatory decisions. The industry dynamics shown in the chart represent the general backdrop of investor expectations and disappointments, against which Aclaris is attempting to prove the effectiveness of its innovative treatment approaches.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of immune-inflammatory diseases. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to demonstrate how scientific news and trial progress have driven its stock price movement independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on immunology and inflammatory diseases. Its weekly stock price is volatile and depends on news of clinical trial results, which could dramatically change investor valuations of the company.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company focused on immunology. Its shares can rise or fall on news about drug trials, defying overall market trends. Use the chart to see how its path is unique compared to the broader pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aclaris is a clinical-stage biopharmaceutical company. Its shares exist in a world of their own, awaiting trial results. The chart clearly shows how its performance is completely disconnected from the stock market and driven solely by scientific breakthroughs and setbacks.
Market capitalization of the company, segment and market as a whole
ACRS - Market capitalization of the company Aclaris Therapeutics
The Aclaris Therapeutics market capitalization chart is a volatile story of a biotech company, full of ups and downs. Its market valuation fluctuates sharply depending on the results of clinical trials of its drugs for the treatment of immunoinflammatory diseases. Any news can lead to a sharp price movement, which is typical for this sector.
ACRS - Share of the company's market capitalization Aclaris Therapeutics within the market segment - Pharma immune
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of immune-inflammatory diseases. Its market share reflects the potential of its developments. Its market capitalization chart is a venture capital story, full of risks and hopes for the next scientific breakthrough.
Market capitalization of the market segment - Pharma immune
Here's a chart showing the biotech sector's market capitalization. Aclaris Therapeutics is a company that has experienced dramatic ups and downs. The market dynamics are full of similar stories. Aclaris's journey, with its successes and failures in clinical trials, is a prime example of how risky and unpredictable biotech investments can be.
Market capitalization of all companies included in a broad market index - GURU.Markets
Aclaris Therapeutics is a biopharmaceutical company focused on developing drugs to treat immune-inflammatory diseases. Its market capitalization reflects the potential of its research and development. The chart below shows the economic weight of companies at the forefront of immunology.
Book value capitalization of the company, segment and market as a whole
ACRS - Book value capitalization of the company Aclaris Therapeutics
Aclaris Therapeutics' foundation is its intellectual property in a portfolio of small molecules for the treatment of immunoinflammatory diseases. Its book value is primarily cash flow for R&D. The chart is a financial timeline of the biotech company, showing how clinical trial results impact its ability to raise capital and fund development.
ACRS - Share of the company's book capitalization Aclaris Therapeutics within the market segment - Pharma immune
Aclaris Therapeutics focuses on immunology and dermatology. The chart shows its share of actual R&D assets. These are its research laboratories where research is conducted to develop new drugs for the treatment of diseases caused by immune system disorders.
Market segment balance sheet capitalization - Pharma immune
Aclaris Therapeutics is a biotech company whose value is locked into its development pipeline. It's a capital-light business. The chart below reflects the capital intensity of the pharmaceutical sector, highlighting its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Aclaris Therapeutics is a biopharmaceutical company focused on immunology and dermatology. Its assets provide capital for clinical research. A modest stake in BCap_All provides material resources for the discovery of new treatments for diseases caused by immune system disorders.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company. Its market capitalization is close to its book value (primarily cash). This suggests that, after past setbacks, the market is taking a wait-and-see approach and isn't pricing in a high probability of success.
Market to book capitalization ratio in a market segment - Pharma immune
Aclaris Therapeutics is a biotech company focused on immunology and dermatology. Its value is determined by the potential of its pipeline drugs. This metric represents a significant premium to book value, reflecting investor expectations for the success of clinical trials.
Market to book capitalization ratio for the market as a whole
Aclaris Therapeutics is a biotech company focused on immunology and dermatology. Its valuation depends almost entirely on the success of clinical trials. This chart demonstrates how market value in the biotech sector can be detached from book value, reflecting investor expectations for future drugs.
Debts of the company, segment and market as a whole
ACRS - Company debts Aclaris Therapeutics
Aclaris Therapeutics, a biopharmaceutical company, uses debt financing to advance its research in immunology and dermatology. Capital is vital for conducting clinical trials and research that could lead to new treatments. The chart shows the financial investment in the company's scientific potential.
Market segment debts - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company focused on immunology and dermatology. During clinical development, companies typically avoid debt financing. This chart shows whether Aclaris adheres to this industry-standard model or utilizes unconventional financing tools to accelerate its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company focused on immunology. Developing new drugs is a lengthy and expensive process, often financed by debt until profitability is achieved. This chart illustrates the company's reliance on lenders to continue its research and development, a key risk factor.
Market segment debt to market segment book capitalization - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company focused on immunology and dermatology. This chart reflects debt trends in their sector. It helps assess how the company is managing the financing of its clinical programs following strategic changes and how its current debt load compares to the prospects of its investigational drugs.
Debt to book value of all companies in the market
Aclaris Therapeutics is a biopharmaceutical company focused on immunology and dermatology. Being in the development and clinical trials stage, Aclaris, like many biotechs, is likely financed through equity rather than debt. This chart of total market debt helps us understand how atypical its financial model is compared to mature industrial or financial companies.
P/E of the company, segment and market as a whole
P/E - Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company focused on developing treatments for immune-inflammatory diseases. This chart shows that the company's valuation is based on the potential of its scientific developments, not current revenue. Investors are betting on the success of clinical trials and future approval of its drugs.
P/E of the market segment - Pharma immune
This industry chart for biotech companies provides key context for Aclaris Therapeutics. It reflects overall speculative valuations in the sector. Comparisons with it help understand whether Aclaris's immunology and dermatology pipeline is more or less optimistically valued by the market than other biotechs at similar stages.
P/E of the market as a whole
Aclaris Therapeutics is a biopharmaceutical company focused on immunology and dermatology. After several strategic shifts, its future hinges on the success of new developments. This chart of overall biotech risk appetite shows whether investors are willing to give the company a second chance and fund its research, despite past setbacks.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of immune-inflammatory diseases. This chart reflects speculative investor expectations. The valuation depends almost entirely on the clinical trial results of its drug candidates and confidence in their future commercial potential.
%20P%2FE%20Aclaris%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aclaris-Therapeutics&v=1772513754991 "Chart of the company's future (projected) P/E Aclaris Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company focused on developing new treatments for immune-inflammatory diseases. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess the market's confidence in its scientific developments and the commercialization potential of future drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513755010 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Aclaris Therapeutics is a biopharmaceutical company developing drugs for the treatment of immune-inflammatory diseases. Against the backdrop of general market expectations, as illustrated by this chart, Aclaris's business is driven by scientific advances. The success of its clinical trials and the potential of its molecules are the primary factors driving the company's value.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513755038 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of immune-inflammatory diseases. The company is in clinical trials. This chart shows the financial health of the company, which is spending heavily on R&D in the hopes of achieving future commercial success.
Profit of companies in the market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company developing treatments for immune-inflammatory diseases. This chart shows profitability in the immunology sector. For ACRS, this represents a market context that evaluates scientific innovations in the treatment of conditions such as psoriasis and rheumatoid arthritis, where there is a high need for new drugs.
Overall market profit
Aclaris Therapeutics is a biotech company specializing in the development of treatments for immune-inflammatory diseases. Its future depends entirely on the results of clinical trials and regulatory approval. The general economic trends reflected in this chart have minimal impact on the scientific process and the valuation of such companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aclaris Therapeutics
Aclaris Therapeutics is a biotechnology company focused on developing drugs for the treatment of immune-inflammatory diseases. The revenue projections presented here are speculative and depend on the success of its clinical programs. Analysts are closely monitoring trial data, which may confirm or refute the potential of its molecules.
%20profit%20of%20the%20company%20Aclaris%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aclaris-Therapeutics&v=1772513755083 "Graph of future (projected) profit of the company Aclaris Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company developing drugs for the treatment of immune-inflammatory diseases. The revenue forecast for this sector depends on the results of clinical trials and the potential of new treatments. This chart reflects the analysts' collective confidence in the commercial success of innovative drugs in dermatology and rheumatology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513755092 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Aclaris Therapeutics is a biopharmaceutical company developing treatments for immune-inflammatory diseases. Its valuation depends on clinical trial results. Market-wide profit forecasts, reflected here, impact the availability of capital for the biotech sector, which is critical for funding R&D.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513755131 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aclaris Therapeutics
Aclaris Therapeutics is a biotech company developing drugs to treat immune-inflammatory diseases. This chart shows the speculative valuation typical for a company in clinical trials. The valuation fluctuates based on trial results, reflecting the binary nature of risk in biotech.
P/S market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company focused on developing new treatments for immune-inflammatory diseases. The company is currently in clinical trials. This chart shows the average revenue estimate in the biotech sector, which helps understand investor expectations for Aclaris's research and development pipeline.
P/S of the market as a whole
Aclaris Therapeutics is a biopharmaceutical company focused on developing new treatments for immune-inflammatory diseases. The company is in clinical trials, and its future value depends on their success. This chart provides a general market backdrop for assessing investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company developing novel treatments for immune-inflammatory diseases. This chart shows how investors estimate the company's future, yet-to-be-realized revenue based on the potential of its research and clinical trials.
%20P%2FS%20Aclaris%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aclaris-Therapeutics&v=1772513755227 "The graph of the company's future (projected) P/S Aclaris Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company developing drugs to treat immune-inflammatory diseases. Like many biotech companies, its value is based on the potential of its pipeline. This chart reflects the market's assessment of its scientific approach and chances of success in clinical trials compared to its competitors.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513755235 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for immune-inflammatory diseases. Their future depends on the success of clinical trials. This market optimism chart is important for ACRS. Investors' high risk appetite, typical during growth periods, provides the capital needed to fund their R&D.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513755251 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immune-inflammatory diseases. Currently, the company has no approved drugs on the market, so its revenue is minimal. This graph will ultimately demonstrate its ability to commercialize its research and development.
Sales of companies in the market segment - Pharma immune
Aclaris Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for immune-inflammatory diseases. Their goal is to create innovative therapies for patients with unmet medical needs. The company currently has no commercial revenue from product sales.
Overall market sales
Aclaris Therapeutics is a biopharmaceutical company developing treatments for immune-inflammatory diseases. Its research is focused on creating new medicines for patients with unmet medical needs. This revenue chart includes the healthcare sector, where ACRS strives to offer innovative solutions for complex diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company developing drugs for the treatment of immune-inflammatory diseases. After selling its commercial assets, it focused on clinical trials. This chart reflects analysts' speculative expectations for the success of its new programs and their potential for treating diseases such as rheumatoid arthritis.
%20sales%20of%20the%20company%20Aclaris%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aclaris-Therapeutics&v=1772513755410 "Schedule of future (projected) sales of the company Aclaris Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company focused on developing new treatments for immune-inflammatory diseases. This chart shows growth forecasts for the overall autoimmune disorder drug market. It illustrates the expected demand for innovative therapies in this area, where Aclaris is seeking to carve out a niche.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513755412 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Aclaris Therapeutics, a biotech company focused on immunology and dermatology, sees this chart as a reflection of the investment climate in the pharmaceutical industry. The stable economic growth projected here provides the capital needed to conduct clinical trials and bring new drugs to market for the treatment of inflammatory diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513755429 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company focused on immunology and dermatology. Being in the development stage, its financial picture is determined by high clinical trial costs. This chart illustrates not current profits, but rather the "cost of innovation"—the investment required to bring new treatments to market.
Market segment marginality - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company focused on developing new treatments for immunoinflammatory diseases. This chart reflects the commercial potential of its pipeline. If successful, high operating income will confirm its pipeline's demand and innovative nature.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company focused on developing drugs to treat immune-inflammatory diseases. This graph shows a small but dedicated team of scientists conducting clinical trials of new molecules. Their work represents a risky but potentially highly significant search for new treatments.
Share of the company's employees Aclaris Therapeutics within the market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company focused on developing treatments for immune-inflammatory diseases. Clinical research and development in this complex field requires a team of highly qualified scientists and physicians. This chart reflects the research intensity of its business, demonstrating the talent it concentrates in its therapeutic niche.
Number of employees in the market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company developing drugs to treat immune-inflammatory diseases. This graphic shows a team of research scientists working at the forefront of immunology, seeking new ways to combat diseases caused by immune system malfunctions, from skin conditions to arthritis.
Number of employees in the market as a whole
Aclaris Therapeutics is a biopharmaceutical company focused on immunology and dermatology. While their work is focused on scientific research, the economic context reflected in this chart is important. A stable labor market supports the healthcare system, and investors are willing to fund the long-term research needed to bring new breakthrough drugs to market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aclaris Therapeutics (ACRS)
Aclaris Therapeutics is a biopharmaceutical company focused on immunology. For companies in clinical development, this chart reflects investor expectations. The high market capitalization per employee is not an estimate of current sales, but a bet that a small team of scientists will create a breakthrough drug that will capture a multi-billion-dollar market niche.
%20of%20the%20company%20Aclaris%20Therapeutics%20(ACRS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aclaris-Therapeutics-ACRS&v=1772513755498 "Chart of market capitalization per employee (in thousands of dollars) of the company Aclaris Therapeutics (ACRS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Aclaris Therapeutics is a biopharmaceutical company focused on immunology and dermatology. Its market capitalization is based on the potential of its pipeline and research. This chart shows the market's valuation of its intellectual capital per employee, an important indicator for the biotech sector.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513755533 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Aclaris Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of immune-inflammatory diseases. In biotech, this metric is a measure of innovative potential. It reflects the market valuation of its scientific developments, where a single molecule breakthrough can lead to the creation of a multi-billion-dollar product.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513755573 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aclaris Therapeutics (ACRS)
Aclaris Therapeutics is a clinical-stage biotech focused on immunology and dermatology. This chart reflects their current status: they are spending money on R&D. Their research staff is working on developing new drugs. Their profit margin is negative, as the company is investing in research that may generate future revenue.
%20Chart%20Aclaris%20Therapeutics%20(ACRS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aclaris-Therapeutics-ACRS&v=1772513755585 "Company Profit Per Employee (in thousands of dollars) Chart Aclaris Therapeutics (ACRS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Aclaris Therapeutics is a biotech company focused on developing treatments for immune-inflammatory diseases. While in the R&D stage, the company actively invests in research. This chart shows the industry average per employee. For Aclaris, whose employees are scientists and clinicians, it serves as a contrasting indicator of the potential profitability of the sector should their drugs be successful.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513755586 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Aclaris Therapeutics is a biotech company focused on developing drugs for the treatment of inflammatory and immunological diseases. It is an R&D company. This chart does not show current profits, but rather the investment (R&D costs) per scientist required to discover and advance new molecules through complex and expensive clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513755610 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aclaris Therapeutics (ACRS)
Aclaris Therapeutics is a biopharmaceutical company focused on immunology and dermatology. The current schedule reflects the clinical development stage. Future revenue growth per employee will depend on the successful approval and launch of its drugs, which will be a key transition from research to commercialization.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aclaris-Therapeutics-ACRS&v=1772513755616 "Sales chart per company employee Aclaris Therapeutics (ACRS)")
Sales per employee in the market segment - Pharma immune
Aclaris Therapeutics is a clinical-stage biotech focused on immunology and dermatology. They have promising developments but lack stable sales. This chart is typical for an R&D company: it shows how their research staff generates minimal (or no) revenue compared to pharma companies with blockbusters.
Sales per employee for the market as a whole
Aclaris Therapeutics is a biotech company focused on developing drugs to treat complex immune-inflammatory diseases. It's a pure R&D company. This graph will likely reflect minimal or no revenue, as their research team is in clinical trials and does not yet have a commercial product.
Short shares by company, segment and market as a whole
Shares shorted by company Aclaris Therapeutics (ACRS)
Aclaris (ACRS) is a clinical-stage biotech focused on developing drugs to treat immune-inflammatory diseases. This chart shows the volume of bearish bets. The high short interest reflects investor doubts about the success of its clinical trials after previous failures, as well as the intense competition in the immunology field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aclaris-Therapeutics-ACRS&v=1772513755678 "Short Shares Chart for the Company Aclaris Therapeutics (ACRS)")
Shares shorted by market segment - Pharma immune
Aclaris (ACRS) is a biotech company focused on immunology and inflammatory diseases. This chart demonstrates the general skepticism in the biotech sector. It summarizes bearish bets, reflecting investor concerns about clinical trial results or funding across the industry.
Shares shorted by the overall market
Aclaris Therapeutics is a clinical-stage biotech company. Its value is tied to the success of its drugs. When market pessimism (as shown in this chart) increases, investors become extremely risk-averse. This makes it extremely difficult for biotechs without revenue to raise the funding needed for research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aclaris Therapeutics (ACRS)
Aclaris Therapeutics (ACRS) is a biotech company focused on developing drugs to treat immune-inflammatory skin diseases (dermatitis, psoriasis). This chart measures hype. It shows "overheated" (above 70) due to positive R&D data or "oversold" (below 30) due to clinical trial failures or delays, which is typical for biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aclaris-Therapeutics-ACRS&v=1772513755682 "RSI 14 indicator chart for the company's stock Aclaris Therapeutics (ACRS)")
RSI 14 Market Segment - Pharma immune
Aclaris (ACRS) is a biotech company specializing in developing small molecule drugs for the treatment of immunological and inflammatory diseases, such as rheumatoid arthritis. This chart tracks overall sentiment in the Pharma/Immunology sector. It helps investors understand whether ACRS's performance reflects its trials or whether the overall sector is overheated or oversold.
RSI 14 for the overall market
Aclaris Therapeutics (ACRS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ACRS (Aclaris Therapeutics)
Aclaris Therapeutics is a clinical-stage biotech focused on developing novel treatments for immune-inflammatory diseases. This chart shows the average analyst price target, which is speculative and reflects their assessment of the company's R&D pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ACRS-Aclaris-Therapeutics&v=1772513755732 "A chart showing analyst consensus forecasts for the expected stock price. ACRS (Aclaris Therapeutics)")
The difference between the consensus estimate and the actual stock price ACRS (Aclaris Therapeutics)
Aclaris Therapeutics is a clinical-stage biotech focused on immunology and inflammatory diseases. Their valuation is entirely dependent on R&D. This chart reflects analysts' speculative expectations regarding their clinical pipeline and the likelihood of success of their lead drug candidates in future trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ACRS-Aclaris-Therapeutics&v=1772513755747 "A chart showing the difference between the consensus forecast and the actual stock price. ACRS (Aclaris Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Aclaris (ACRS) is a biotech company developing drugs to treat complex immunoinflammatory diseases. This is a risky R&D business. This chart shows analysts' overall expectations for the entire immunopharmaceutical sector. It reflects whether experts believe breakthroughs in this field are possible or whether they expect a funding freeze.
Analysts' consensus forecast for the overall market share price
Aclaris Therapeutics is a biotech company specializing in the development of drugs for the treatment of immune-inflammatory diseases (dermatology, rheumatology). This chart shows the overall risk appetite. For Aclaris, as a clinical-stage company whose value depends on the success of trials, overall market optimism is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biotech focused on developing small molecules (tablets) for the treatment of autoimmune and inflammatory diseases (immunology). This chart is a pure indicator of faith in their science. It doesn't reflect revenue, but rather a speculative estimate of their R&D progress and clinical trial data, which dictate their volatility.
AKIMA Market Segment Index - Pharma immune
Aclaris Therapeutics is a biotech company developing drugs to treat immune-inflammatory diseases. This chart shows the average index for the immunology sector. It provides investors with a benchmark for how Aclaris' clinical-stage scientific platform compares to the sector average across a range of factors.
The AKIM Index for the overall market
Aclaris Therapeutics is a biopharmaceutical company developing drugs for the treatment of immune-inflammatory diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is undergoing a strategic pipeline reorientation, compares to overall economic trends in biotech.
